Cellular immunotherapy in multiple myeloma

Vo, Manh-Cuong; Lakshmi, Thangaraj Jaya; Jung, Sung‐Hoon; Cho, Duck; Park, Hye-Seong; Chu, Tan-Huy; Lee, Hyunju; Kim, Hyeoung-Joon; Kim, Sang‐Ki; Lee, Je‐Jung

doi:10.3904/kjim.2018.325

Cited by 10 publications

(6 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune dysfunction leads to MM tumor cell immune evasion, thereby promoting MM progression. − Immune dysfunction includes the loss of immunogenicity against the malignant PC population via the immune editing upregulation of inhibitory ligands that promote immune tolerance and T-cell exhaustion as well as the development of an immunosuppressive tumor microenvironment that fosters tolerance and immune escape . Consistently, we noted that the differentially expressed proteins identified in our study showed predicted functions related to the modulation of apoptosis, programmed cell death, cellular protein metabolism, immunity and host defense responses, and growth signaling pathways.…”

Section: Discussionsupporting

confidence: 78%

Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma

et al. 2021

View full text Add to dashboard Cite

Multiple myeloma (MM) is a common hematological malignancy with poorly understood recurrence and relapse mechanisms. Notably, bortezomib resistance leading to relapse makes MM treatment significantly challenging. To clarify the drug resistance mechanism, we employed a quantitative proteomics approach to identify differentially expressed protein candidates implicated in bortezomib-resistant recurrent and relapsed MM (RRMM). Bone marrow aspirates from five patients newly diagnosed with MM (NDMM) were compared with those from five patients diagnosed with bortezomib-resistant RRMM using tandem mass tag-mass spectrometry (TMT-MS). Subcellular localization and functional classification of the differentially expressed proteins were determined by gene ontology, Kyoto Encyclopedia of Genes and Genomes pathway, and hierarchical clustering analyses. The top candidates identified were validated with parallel reaction monitoring (PRM) analysis using tissue samples from 11 NDMM and 8 RRMM patients, followed by comparison with the NCBI Gene Expression Omnibus (GEO) dataset of 10 MM patients and 10 healthy controls (accession no.: GSE80608). Thirty-four differentially expressed proteins in RRMM, including proteinase inhibitor 9 (SERPINB9), were identified by TMT-MS. Subsequent functional enrichment analyses of the identified protein candidates indicated their involvement in regulating cellular metabolism, apoptosis, programmed cell death, lymphocyte-mediated immunity, and defense response pathways in RRMM. The top protein candidate SERPINB9 was confirmed by PRM analysis and western blotting as well as by comparison with an NCBI GEO dataset. We elucidated the proteome landscape of bortezomib-resistant RRMM and identified SERPINB9 as a promising novel therapeutic target. Our results provide a resource for future studies on the mechanism of RRMM.

show abstract

Section: Discussionsupporting

confidence: 78%

Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…According to information available by Oncologia Brasil on its own website in the year 2019, the most prevalent average age of MM carriers was 63 years, being mostly male (VO et al. 2019).…”

Section: Introductionmentioning

confidence: 99%

“…MM is considered an incurable disease, but it is treatable. It is common that its carriers present modifications in the production of other blood cells, being observed alterations in the hemogram, such as anemia, thrombocytopenia and leukopenia (DOS SANTOS et al, 2022;VO et al, 2019;MILANI;FERNANDES, 2018).…”

Section: Introductionmentioning

confidence: 99%

Multiple myeloma: a clinical case report

Alferes-Araújo,

Raymundo,

Cola

et al. 2023

CLIUM

View full text Add to dashboard Cite

Objective: To report and discuss the clinical and histopathological findings of a case of multiple myeloma in the jaw region. Case Report: A 58 year old female patient came to UNIPAR Dentistry School complaining of "increased volume on the left side of the face". On physical examination it was observed intact mucosa with buccal cortical expansion in the region of the teeth 34/35/36 and asymptomatic. Radiographic examination revealed a radiolucent area approximately 25 mm in diameter. An incisional biopsy was performed and the histopathological diagnosis was suggestive of plasmacytoma/multiple myeloma, and after finding other lesions it was confirmed as multiple myeloma. The patient was then referred to a hematologist who, together with the oncologist, established the treatment. Conclusion: Although treatment is a medical responsibility, the dental surgeon has an important role in the early diagnosis of this disease, since some of its first clinical and radiographic findings are related to the maxillomandibular complex.

show abstract

“…Currently, the standard treatment strategy for MM is high-dose chemotherapy (such as carfilzomib, bortezomib and melphalan) followed by stem cell transplantation (if accessible), which effectively prolongs patient survival time (4). However, due to its complexity, MM remains a challenge to treat, and its precise pathogenic mechanisms have not been fully clarified (5,6). Therefore, it is important to determine the lncRNA transcription factor 7 is related to deteriorating clinical features and poor prognosis in multiple myeloma, and its knockdown suppresses disease progression by regulating the miR-203-mediated Jagged1-Notch1 signaling pathway underlying etiology of MM and to identify potential new treatment targets.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

lncRNA transcription factor 7 is related to deteriorating clinical features and poor prognosis in multiple myeloma, and its knockdown suppresses disease progression by regulating the miR‑203‑mediated Jagged1‑Notch1 signaling pathway

Liu

Shen

et al. 2021

Oncol Lett

View full text Add to dashboard Cite

Multiple myeloma (MM) remains a challenge to treat, and its precise pathogenic mechanisms have not been fully clarified. The present study aimed to evaluate the relation between long non-coding RNA transcription factor 7 (lnc-TCF7) and clinical features, as well as the prognosis of patients with MM, and to determine the effects of lnc-TCF7-knockdown on the regulation (and regulatory mechanisms) of MM progression. lnc-TCF7 expression was detected in the bone marrow plasma cells of 86 patients with MM and 30 healthy controls. In patients with MM, the clinical data were collected, and event-free survival (EFS) and overall survival (OS) analyses were conducted. In vitro, lnc-TCF7 expression was detected in MM cell lines and normal bone marrow plasma cells. Using Roswell Park Memorial Institute 8226 cells, functional experiments were conducted following lnc-TCF7 short hairpin (sh)RNA transfection, and compensation experiments were performed after lnc-TCF7 shRNA transfection alone and in combination with a microRNA (miR)-203 inhibitor. lnc-TCF7 expression was increased in patients with MM compared with the healthy controls and was positively related to β-2-microglobulin expression and International Staging System stage, while negatively associated with complete response, EFS and OS. In vitro, lnc-TCF7 was upregulated in MM cells compared with normal bone marrow plasma cells, and its knockdown suppressed MM cell proliferation while promoting apoptosis. Compensation experiments showed that miR-203 inhibition promoted MM progression by regulating the Jagged1-Notch1 signaling pathway in lnc-TCF7-knockdown cells. In conclusion, increased lnc-TCF7 expression was related to deteriorating clinical features and prognosis, and lnc-TCF7-knockdown inhibited disease progression by regulating the miR-203-mediated Jagged1-Notch1 signaling pathway activation in MM.

show abstract

Cellular immunotherapy in multiple myeloma

Cited by 10 publications

References 73 publications

Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma

Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma

Multiple myeloma: a clinical case report

lncRNA transcription factor 7 is related to deteriorating clinical features and poor prognosis in multiple myeloma, and its knockdown suppresses disease progression by regulating the miR‑203‑mediated Jagged1‑Notch1 signaling pathway

Contact Info

Product

Resources

About